asa guidelines for glp 1 agonists The New Weight Management Meds GLP-1 medications safe to continue

Glucagon-like peptide 1 receptor agonists and heart failure: the need for further evidence generation and practice guidelines optimization

New England Journal of Medicine -published SURMOUNT-5 trial confirmed Zepbound's superior weight reduction in a head-to-head comparison

Effectiveness is equivalent with proper sourcing and administration

Novel strategies in the oral delivery of antidiabetic peptide drugs-Insulin, GLP 1 and its analogs

In Their Own Words In recent years, GLP-1 receptor agonists like semaglutide (sold under brand names Ozempic and Wegovy) have become revolutionary treatments for obesity and type 2 diabetes, offering substantial weight loss, and myriad other benefits including improved renal and cardiovascular health